GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML
Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...
Company
Cochlear’s Artificial Cochlear Sound Processor Gains NMPA Approval for Marketing in China
Australia-based Cochlear has received marketing approval from the National Medical Products Administration (NMPA) for its...
Jiangsu Recbio Forms Strategic Cooperation for Vaccine Production in Zimbabwe
China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced a tripartite strategic cooperation agreement...
Roche’s Forimtamig Receives Tacit Approval for Multiple Myeloma Clinical Trials
The Center for Drug Evaluation (CDE) has indicated that Swiss pharmaceutical giant Roche (SWX: ROG)...
Sanofi Partners with BioMap to Accelerate AI-Driven Drug Discovery
France-based pharmaceutical giant Sanofi (EPA: SAN) has entered into a strategic partnership with US biotech...
Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical
China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2%...
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan
Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm...
Bayer Opens First Cell Therapy Production Facility in the U.S. to Advance Research
Bayer AG (ETR: BAYN) has inaugurated its first production site dedicated to cell therapies, marking...
AstraZeneca Seeks Approval for Capivasertib in Combination with Faslodex for Breast Cancer Treatment
AstraZeneca (AZ, NASDAQ: AZN) has submitted a market approval filing for its Category 1 drug...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Anti-Tumor Drug Candidate SHR-2022
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
China NT Pharma Group Enters MOU with Global Fund to Expand Orthopedic Product Line
China NT Pharma Group Company Ltd (HKG: 1011), a China-based pharmaceutical company, has announced the...
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical...
Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation
Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million...
Atom Bioscience Initiates Global Phase III Clinical Study for Gout Drug ABP-671
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced the enrollment of...
GluBio Pharmaceutical’s GLB-002 Receives NMPA Approval for Clinical Trials in Hematological Tumors
GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in...
Med Vision’s Sleep Disorder Software Receives Category II Approval in China
Hangzhou-based Med Vision, a provider of virtual reality (VR)-enabled digital therapeutics (DTx) solutions, has reportedly...
Luye Pharma Files NDA for Paliperidone Palmitate Injectable Suspension with US FDA
China-based Luye Pharma Group (HKG: 2186) has announced the submission of a New Drug Application...
Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...